Article: article from journal or magazin.
Nouvelles thérapies en rhumatologie pédiatrique [New therapies in pediatric rheumatology].
Revue Médicale Suisse
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Biotherapies are recent treatments, which target molecules implicated in the pathogenesis of inflammatory diseases. In pediatric rheumatology, we use anti-TNF-alpha and abatacept in JIA patients with polyarticular involvement, whereas anti-IL-6 and anti-IL-1 blockers are efficacious in the systemic form of JIA and other auto-inflammatory conditions. These new treatments have significantly improved the control of articular and systemic inflammation and the prognosis of rheumatic diseases. Their effect and their safety on the long-term need to be assessed on large cohorts of patients. Due to the impact of these chronic illnesses on the young patient and its family, and the required specific knowledge, the care of these children should be provided by a multidisciplinary team linked to a centre of competence.
Biological Agents/therapeutic use, Child, Humans, Rheumatic Diseases/drug therapy
Last modification date